1. Information about this Guideline – Cervical Carcinoma

Office Leitlinienprogramm Onkologie
c/o Deutsche Krebsgesellschaft e. V.
Kuno-Fischer-Straße 8
14057 Berlin

leitlinienprogramm@krebsgesellschaft.de
www.leitlinienprogramm-onkologie.de

 

Leitlinienprogramm-Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnosis, Treatment, and Follow-Up in Patients with Cervical Carcinoma, Langversion 2.2, 2022, AWMF-Registernummer 032/033OL, https://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom/

April 2021: Version 1.1: Correction of Figure 1  / Figure 3 (alteration of the stages in the footnotes) and Figure 5 (addition to the legend).

March 2022: Version 2.2: Addition of references to the definition of deep stromal infiltration (see 7.2.4) in recommendation 8.8 and Chapter 6.3.

 

The field of medicine is subject to a continuous process of further development, so that all details provided here, and in particular those on diagnostic and therapeutic procedures, can always only represent the state of knowledge at the time when the medical care guideline was printed. The greatest possible care has been taken with regard to the treatment recommendations given and to the choice and dosage of drugs. However, users are requested to check by referring to the patient package inserts and specialist information provided by the manufacturers, and in cases of doubt to consult a specialist. In the general interest of the guideline editors, readers are requested to draw attention to any questionable points or inconsistencies found.

Users themselves remain responsible for all diagnostic and therapeutic applications, medications, and dosages.

Registered trademarks (protected proprietary names) are not specially identified in this guideline. The absence of an indication of this type can therefore not be taken to suggest that such names are unregistered product names.

All parts of this guideline are protected by copyright. Any usage outside of the provisions of copyright law without written permission from the Oncology Guideline Program editors is therefore unlawful and liable to prosecution. No part of this work may be reproduced in any form without written permission from the Oncology Guideline Program editors. This applies in particular to reproduction, translation, microfilming, and storage, usage, and exploitation in electronic systems, intranets and the Internet.

 

The aim of the Association of the Scientific Medical Societies in Germany (AWMF), the German Cancer Society (DKG), and the German Cancer Aid (Deutsche Krebshilfe) in implementing the Oncology Guidelines Programme is to jointly promote and support the development, updating, and use of scientifically based and practicable guidelines.

The program is based on medical and scientific findings established by the the scientific societies and the DKG, consensus among medical experts, users, and patients, as well as the AWMF's regulations for the guideline development. The programme receives specialist support and financing from the German Cancer Aid. In order to reflect the current state of medical knowledge and to take into account medical progress, guidelines have to be regularly checked and updated. The use of the AWMF regulations is intended to provide a basis for developing high-quality oncological guidelines in this framework.

As guidelines represent an important instrument for quality assurance and quality management in oncology, they are intended to be used in a targeted and sustained way in everyday medical care. Active implementation measures and also evaluation programmes are therefore important components of the support provided by the Oncology Guideline Programme.

The aim of the programme is to create professional preconditions, with secure medium-term financing, for the development and provision of high-quality guidelines in Germany. High-quality guidelines of this type not only serve for structured knowledge transfer, but can also be used in the design of the health-care structures. Relevant aspects of this include evidence-based guidelines as a basis for establishing and updating disease management programmes, and the use of quality indicators derived from guidelines in the context of certification procedures for organ tumour centres.

In addition to the present long version of the Level 3 guideline on diagnosis, treatment, and follow-up in patients with cervical carcinoma, the following supplementary documents on the guideline are also available:

• Short version of the guideline
• Patient guideline
• Guideline report on the process of compiling guideline (including evidence)
• Short version – English/German

This guideline and all of the additional documents are available from the following web sites.

• Guideline Program Oncology (https://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom/)
• AWMF (https://www.awmf.org/leitlinien/detail/ll/032-033OL.html)
• Guidelines International Network (www.g-i-n.net)

The guideline is also included in the Guideline Program Oncology app.
Further information is available at: https://www.leitlinienprogramm-onkologie.de/app/